+ Watch THOR
on My Watchlist
The Company manufactures, develops and markets medical devices used for circulatory support.
I like to take a look at companies that show a 20% price change in pre/post market. Sometimes it's a chance to learn, on rare occasions, it's a CAPS or real life play depending on my take of the "news".I didn't find much to like about Thoratec, and the lower forecast put this one at about a $18-21 company, IF it could turn back around. In other words, the punishment pointing toward a 5 year low looked justified, and not a CAPS or real life play. I set a limit order, and decided to come back later to close it unless some new press release gave me new insights.Part of my research showed some old CAPS pitches, (are there any other kind with content, besides a handful), that pointed out how their heart devices were failing, but on counterbalance, they were used in extreme cases where the life of the patient was already on the line. All day, while my limit sat, all I saw was THOR with his hammer everywhere...pop up ads, bumper stickers when I took a walk at lunch, a sign where someone borrowed his image to promote a technological product....and on and on...and all I saw was that hammer, thinking that if I got hit by it, I'd need one of Thoratec Corp's products.....Large sell downs are usually a 2-3 day affair. The low bounce in the morning, a short spike up, short sellers cover, shares remix, day traders jump in, long term holders chew their nails....then near the end of the first day, a late selloff...and that's where we were when I checked in again, and decided that THOR and his hammer might be worth a play anyway...just in case I need them......
long term buy at $33, 1yr target $45, 5yr EPS growth 27%
Thoratec Heartmate II devices say an increase in pump clots and death. Initial FDA reports were of clotting in about 1.2% .. which was true for a while.. during 2012 - for some unknown reasons the clot rate has shot up to 9% or higher depending on who's numbers you use. FDA investigation to pursue I would say.. and there are already class action lawsuits being filed due to the deaths.
THOR has just recently been approved to market the Heartmate ll pump for destination cardiac patients. This allows hope for many thousands of cardiac patients who might have less than a year to live and who are not elgible for or waiting for a transplant.
Solid growth company will outperform the S&P
LT Growth: 24%EPS Surp: Pos last 2 qtrsMF: +Large Volume IncreaeInsight, Driehaus, Fid Contra, Veredus, Calamos, Lord Abbett,Emerald, Kopp, NCM=BUY!
Expect takeover by MDT
another strong biotech company thats well run
People will have bad hearts. Thanks McDonalds
highlighted in IBD Tech. says way ahead of competition in heart pumps. sounds interesting.
This company is a lottery ticket but it's priced like the drawing is already complete. Institutions disposed 3% of their holdings last quarter; insiders acquiring (non open market) and doing same. Why bother with this?
Long term play on aging population.
Increasing medicare coverage that will allow more hospitals to implant the device, improved new product on the verge of approval, best in class.
well managed; great performer over past few years
BTT and DT market have tremendous potential. Will shoot up probably beginning July 2007. Strong potential for a takeover by another company. WIll see $50+ by the end of 2007, if not taken over earlier at a hefty premium.
Totally robotic heart implant FDA approved. new model in testing,should be approved by year end
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions